News

Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today

In collaboration with @Courir pour Elles, @Vivet_tx participated in an 8km walk/run to raise #BreastCancer Awareness and Prevention. Join #TeamVivet in the cause as we

Paris, France, October 22, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic

📢 Leukodystrophy Awareness Month takes place throughout the whole month of September and is a time to raise awareness about these devastating rare conditions! Together

European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX) • Pre-clinical data of VTX-806 in

Paris, France, July 16, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic

We are delighted to share our findings in a peer reviewed paper published in the World Journal of Hepatology, titled ‘Characteristics of patients with Wilson

Vivet Therapeutics Presents Interim Data from its Phase 1/2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024 VTX-801 increased ceruloplasmin ferroxidase

Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease

To mark #RareDiseaseDay on 29 February, our CEO Jean-Philippe Combal, spoke to pharmaphorum

PRESS RELEASE Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis

Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics (“Vivet”), a clinical- stage biotechnology company

Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing Or Underserved Populations Worldwide”.

Wilson Disease is a rare, progressive genetic disorder that causes excess copper to be stored in the body.

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease

Learn how  gene therapy aims to target the cause of  Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.

Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease